Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 241,580
  • Shares Outstanding, K 187,271
  • Annual Sales, $ 0 K
  • Annual Income, $ -148,700 K
  • EBIT $ -105 M
  • EBITDA $ -98 M
  • 60-Month Beta 1.90
  • Price/Sales 115.72
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 138.91% (+0.46%)
  • Historical Volatility 71.56%
  • IV Percentile 79%
  • IV Rank 26.66%
  • IV High 318.33% on 07/10/25
  • IV Low 73.71% on 02/20/25
  • Expected Move (DTE 10) 0.2550 (20.08%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 592
  • Volume Avg (30-Day) 2,592
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 114,611
  • Open Int (30-Day) 121,112
  • Expected Range 1.0150 to 1.5250

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.13
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.13
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0900 +16.51%
on 11/21/25
1.4300 -11.19%
on 11/12/25
-0.0600 (-4.51%)
since 11/07/25
3-Month
1.0900 +16.51%
on 11/21/25
2.5500 -50.20%
on 10/06/25
-0.2300 (-15.33%)
since 09/09/25
52-Week
1.0900 +16.51%
on 11/21/25
6.7700 -81.24%
on 12/20/24
-2.9450 (-69.87%)
since 12/09/24

Most Recent Stories

More News
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEVâ„¢) Clinical Results

– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels –...

HUMA : 1.2700 (-1.55%)
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 1.2700 (-1.55%)
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement -  - Major advances in pipeline as Humacyte moves closer...

HUMA : 1.2700 (-1.55%)
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025

– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – –...

HUMA : 1.2700 (-1.55%)
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial...

HUMA : 1.2700 (-1.55%)
Humacyte Announces Publication of New Data Comparing Symvessâ„¢ to Autologous Vein in Extremity Arterial Trauma

- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein -...

HUMA : 1.2700 (-1.55%)
Humacyte Announces $60M Stock and Warrants Offering

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Humacyte...

HUMA : 1.2700 (-1.55%)
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 1.2700 (-1.55%)
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvessâ„¢

- Results published in Oxford Academic’s Military Medicine Journal - - After up to 18 months of follow-up patients were observed to have zero infections, amputations or deaths and a high rate of...

HUMA : 1.2700 (-1.55%)
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

– Patent covers esophagus produced using Humacyte’s proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus – – Patent provides coverage...

HUMA : 1.2700 (-1.55%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 1.4200
2nd Resistance Point 1.3700
1st Resistance Point 1.3200
Last Price 1.2700
1st Support Level 1.2200
2nd Support Level 1.1700
3rd Support Level 1.1200

See More

52-Week High 6.7700
Fibonacci 61.8% 4.6002
Fibonacci 50% 3.9300
Fibonacci 38.2% 3.2598
Last Price 1.2700
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar